Anti-CD3 Antibody Modulation of Microglial Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a more specific therapeutic targeting system to control microglial cell activation and inhibit amyloid plaque formation in neurodegenerative disorders, as existing methods are inadequate in addressing CNS inflammatory responses and neurological diseases.
Innovation Solution
Administering an anti-CD3 antibody to suppress microglial activation by reducing CD74 and H2-AB1 expression or increasing CX3CR1, TGFβ-1, Ly6Chigh splenocyte expression of CX3CR1, CCR2, Hsp40, or Dusp1, which can be done orally or mucosally, preferably intra-nasally, to treat neurodegenerative, ischemic, traumatic brain injuries, and lysosomal storage diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic methods are used to control microglial cell activation, then general immune suppression may be achieved, but specificity in targeting microglial inflammatory response is insufficient
Solution Approach 1:
The patent uses anti-CD3 antibodies as intermediary molecules that specifically bind to CD3 receptors on microglial cells, enabling selective targeting of microglial inflammatory response without affecting other immune cells. This intermediary approach provides the needed specificity while maintaining manageable system complexity.
Solution Approach 2:
The patent employs parameter changes by modifying antibody characteristics (isotype, affinity, dosage) to optimize microglial targeting specificity. By adjusting these parameters, the therapeutic system achieves reliable specific targeting without requiring overly complex multi-component systems.
2Reliability
If anti-CD3 antibody is administered to suppress microglial activation, then inflammatory markers are reduced, but delivery to CNS requires overcoming blood-brain barrier limitations
Solution Approach 1:
The patent utilizes the nasal mucosa as an intermediary delivery route that bypasses the blood-brain barrier. Anti-CD3 antibodies administered intranasally can directly access CNS tissue through the nasal-olfactory pathway, combining effective drug delivery with straightforward administration.
Solution Approach 2:
The patent replaces the conventional mechanical/invasive delivery methods (injections, surgical administration) with a non-invasive intranasal administration system. This substitution maintains therapeutic efficacy while dramatically improving ease of operation and patient compliance.
3Reliability
If microglial activation is suppressed to treat neurodegenerative disorders, then amyloid plaque formation is reduced, but treatment must address multiple disease manifestations simultaneously
Solution Approach 1:
The patent employs anti-CD3 antibodies with universal multi-functional properties that address multiple disease manifestations simultaneously. A single anti-CD3 antibody treatment can suppress microglial activation, reduce amyloid plaque formation, and alleviate neurological symptoms across different neurodegenerative disorders, providing the needed adaptability.
Solution Approach 2:
The patent uses parameter changes in antibody dosage and administration frequency to adapt treatment to different disease manifestations and severities. By adjusting these parameters, the same anti-CD3 antibody mechanism can effectively treat varying presentations of neurodegenerative disorders.
Data Source
AI summary
The present invention provides methods of suppressing the activation of microglial cells, methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, methods of ameliorating or treating specific diseases that affect the CNS by administering an anti-CD3 antibody.